Related Experiment Videos
Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma
Abstract:
A phase-II trial of 4-demethoxydaunorubicin (4-DMDR) was performed in 21 patients with advanced renal cell carcinoma. The drug had demonstrated a broader spectrum of activity with less cardiotoxicity in preclinical evaluation than the parent compound daunorubicin. The starting dose was 12.5 mg/m2, with escalations to 15 and 17.5 mg/m2 in the absence of toxicity. Myelosuppression was the primary toxicity and cardiac toxicity was not seen in four patients who received four or more doses of DMDR. No responses were seen in 19 adequately treated patients, including 14 who had received no prior therapy.
Insights
This Phase II trial investigated 4-demethoxydaunorubicin (4-DMDR) for advanced renal cell carcinoma. The study found no significant responses, with myelosuppression as the main toxicity.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- 4-demethoxydaunorubicin (4-DMDR) showed preclinical promise for broader activity and reduced cardiotoxicity compared to daunorubicin.
- Advanced renal cell carcinoma (RCC) remains a challenging malignancy with limited treatment options.
Purpose of the Study:
- To evaluate the efficacy and safety of 4-demethoxydaunorubicin (4-DMDR) in patients with advanced renal cell carcinoma.
- To determine the maximum tolerated dose and toxicity profile of 4-DMDR in this patient population.
Main Methods:
- A Phase II clinical trial involving 21 patients with advanced renal cell carcinoma.
- Dosing started at 12.5 mg/m², escalating to 15 and 17.5 mg/m² based on toxicity.
- Primary endpoints included response rate and toxicity assessment, particularly myelosuppression and cardiotoxicity.
Main Results:
- No objective responses were observed in 19 adequately treated patients.
- Myelosuppression was identified as the primary dose-limiting toxicity.
- No cardiac toxicity was observed in four patients who received four or more doses of 4-DMDR.
Conclusions:
- 4-demethoxydaunorubicin (4-DMDR) did not demonstrate efficacy in advanced renal cell carcinoma patients in this Phase II trial.
- Further investigation into 4-DMDR for renal cell carcinoma is not warranted based on these findings.
- The observed toxicity profile, primarily myelosuppression, requires careful consideration in future drug development.